COPA syndrome, an autosomal-dominant inborn error of immunity, is nonpenetrant in ∼20% of individuals, with no known mediators of protection. Recent studies implicate STING in the pathogenesis of COPA syndrome. We show that the common HAQ STING allele mediates complete clinical protection. We sequenced 35 individuals with COPA mutations, 26 affected patients and 9 unaffected carriers, finding HAQ STING co-segregation with clinical nonpenetrance. Exome sequencing identified only the mutations comprising HAQ STING as variants shared by unaffected carriers and absent in patients. Experimentally, we found that HAQ STING acts dominantly to dampen COPA-dependent STING signaling. Expressing HAQ STING in patient cells rescued the molecular phenotype of COPA syndrome. Our study is the first report of a common and well-tolerated allele mediating complete clinical protection from a severe genetic disorder. Our findings redefine the diagnostic criteria for COPA syndrome, expose functional differences among STING alleles with broad scientific and clinical implications, and reveal a potential universal gene therapy approach for patients.
The common HAQ STING allele prevents clinical penetrance of COPA syndrome
Disclosures: N. Simchoni reported a patent to HAQ STING gene therapy for COPA syndrome pending. C.S. Law reported a patent to HAQ STING gene therapy for COPA syndrome pending. M.M.-K. Wong reported owning GeneDx stock (105 shares). R.M. Laxer reported “other” from Eli Lilly, Sanofi, Novartis, Sobi, and Akros Pharma outside the submitted work. D.B. Beck reported personal fees from Sobi, Novartis, GSK, Alexion, and Genesis Therapeutics outside the submitted work. T.P. Vogel reported personal fees from SOBI, Pfizer, Moderna, and Novartis, and “other” from AstraZeneca outside the submitted work, and being a member of the scientific advisory board of the COPA Syndrome Foundation. A.K. Shum reported a patent to HAQ STING gene therapy for COPA syndrome pending. No other disclosures were reported.
